Although more women than men have pulmonary arterial hypertension, several PAH medications are teratogenic, according to a ...

Pulmonary hypertension (PH) has a high mortality rate if untreated. Unfortunately, the disease is not consistently diagnosed or treated across the United States. To improve the diagnosis and care of ...

Reduced diffusing capacity of the lungs for carbon monoxide (DLco) reflects microvasculopathy in chronic thromboembolic ...

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension ...

A 40-year-old woman who was once accustomed to frequent travel suddenly found herself struggling to breathe after just a few ...

Estimated YUTREPIA™ net product sales of approximately $90.1 million in the fourth quarter and $148.3 million for full-year ...

Liquidia › Biotech Liquidia (NASDAQ: LQDA) had good news to report about its latest commercialized product as the trading ...

Estimated YUTREPIA net product sales of approximately $90.1 million in the fourth quarter and $148.3 million for full-year 2025Received more than 2,800 unique patient prescriptions since launch in Jun ...

With a $125 million series B financing round, Diagonal Therapeutics has made a vertical move to advance its first-in-class ...

Merck is in talks ​to buy cancer drug developer Revolution Medicines in a USD 28 billion ⁠to USD 32 billion deal, the ...

Proceeds to fund clinical development of DIAG723, a first-in-class, disease-modifying therapy designed to correct the root cause of hereditary hemorrhagic telangiectasia and pulmonary arterial ...

Women with pulmonary hypertension have a lower risk of death than men, suggesting sex should be considered as a risk factor, ...